Indications

Renal Disease

  • 100+ clinical sites in Germany, Poland, Bulgaria, Romania
  • 150+ investigators in renal disease indications
  • Completion of two clinical programs for biosimilar Erythropoetin zeta, branded as Silapo®/Retacrit®
  • Immunogenicity trials
  • Therapeutic equivalence trials
  • Pharmacokinetic trials in patients

Renal failure and renal anemia

  • five phase III trials in 1800 patients on haemodialysis

Chronic Kidney Disease

  • two phase III trials in 1050 patients